Second-line treatment of primary biliary cholangitis: To whom, which molecule, and when

doi:10.4254/wjh.121491

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

(5)

(3)

(0)

(44)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Aug 27, 2026; 18(8): 121491
Published online Aug 27, 2026. doi: 10.4254/wjh.121491

Full Size Figure Download Figure

Figure 1 Considerations of the indication for second-line primary biliary cholangitis treatment and its timing. Elafibranor and seladelpar are approved drugs for second-line primary biliary cholangitis treatment. Fibrates should be considered in countries where approved agents are unavailable or not reimbursed. UDCA: Ursodeoxycholic acid.

Citation: Drazilova S, Jarcuska P, Koky T, Harhovsky M, Komarova S, Vasil J, Janicko M. Second-line treatment of primary biliary cholangitis: To whom, which molecule, and when. World J Hepatol 2026; 18(8): 121491
URL: https://www.wjgnet.com/1948-5182/full/v18/i8/121491.htm
DOI: https://dx.doi.org/10.4254/wjh.121491

Drazilova S, Jarcuska P, Koky T, Harhovsky M, Komarova S, Vasil J, Janicko M. Second-line treatment of primary biliary cholangitis: To whom, which molecule, and when. World J Hepatol 2026; 18(8): 121491 [DOI: 10.4254/wjh.121491]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.